Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Director Sells $385,000.00 in Stock

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Director Molly Harper sold 17,500 shares of the firm’s stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $22.00, for a total transaction of $385,000.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Catalyst Pharmaceuticals Stock Down 1.2 %

NASDAQ CPRX opened at $22.07 on Monday. Catalyst Pharmaceuticals, Inc. has a 52 week low of $13.00 and a 52 week high of $24.27. The company has a 50 day moving average price of $21.26 and a 200 day moving average price of $18.79. The firm has a market cap of $2.63 billion, a PE ratio of 18.70, a price-to-earnings-growth ratio of 3.40 and a beta of 0.75.

Hedge Funds Weigh In On Catalyst Pharmaceuticals

A number of large investors have recently made changes to their positions in the business. Susquehanna Fundamental Investments LLC acquired a new stake in Catalyst Pharmaceuticals in the second quarter worth about $258,000. Integral Health Asset Management LLC purchased a new stake in Catalyst Pharmaceuticals during the 2nd quarter worth approximately $4,260,000. GSA Capital Partners LLP purchased a new stake in Catalyst Pharmaceuticals during the 3rd quarter worth approximately $625,000. Vanguard Group Inc. increased its stake in Catalyst Pharmaceuticals by 12.1% during the 1st quarter. Vanguard Group Inc. now owns 7,980,661 shares of the biopharmaceutical company’s stock valued at $127,212,000 after purchasing an additional 860,244 shares in the last quarter. Finally, Capstone Investment Advisors LLC purchased a new position in shares of Catalyst Pharmaceuticals in the third quarter worth $708,000. 79.22% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on CPRX shares. Stephens initiated coverage on Catalyst Pharmaceuticals in a report on Monday, November 18th. They issued an “overweight” rating and a $35.00 target price for the company. Citigroup increased their target price on shares of Catalyst Pharmaceuticals from $27.00 to $31.00 and gave the stock a “buy” rating in a report on Friday, August 9th. StockNews.com upgraded shares of Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Friday, August 9th. Truist Financial increased their price objective on shares of Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the company a “buy” rating in a research note on Monday, November 11th. Finally, HC Wainwright reissued a “buy” rating and issued a $30.00 price objective on shares of Catalyst Pharmaceuticals in a research note on Friday, November 8th. Seven investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $31.14.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.